Investigational Immunotherapy SRF231 Granted FDA Orphan Drug Status for Multiple Myeloma
The U.S. Food and Drug Administration has granted orphan…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
CHMP Recommends Darzalex Combo Therapy for Certain Newly Diagnosed Multiple Myeloma Patients
Expanded use of Darzalex (daratumumab) in combination with standard therapy…
Machine-learning Algorithm Predicts Responses to Myeloma Treatments
Inserting data from genetically similar patients into a machine-learning…
Urine Tests May Be Better Than Serum for Multiple Myeloma Screening, Study Suggests
Urine tests may be better than serum…
Karyopharm Seeks Selinexor’s Accelerated Approval in US for Heavily Treated Myeloma Patients
Karyopharm Therapeutics is seeking accelerated approval for its…
Ninlaro Could Replace First-line Velcade in Older Myeloma Patients, Study Suggests
Older multiple myeloma patients who are unable to receive…
